articleTop 1% cited
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
European Journal of Cancer · 2016 · Vol. 60 · pp. 190–209
Lars Hofmann(Friedrich-Alexander-Universität Erlangen-Nürnberg)Andrea Forschner(University Children's Hospital Tübingen)Carmen Loquai(Johannes Gutenberg University Mainz)Simone M. Goldinger(University Hospital of Zurich)Lisa Zimmer(University of Duisburg-Essen)Selma Ugurel(University of Duisburg-Essen)Maria Isabel Schmidgen(Johannes Gutenberg University Mainz)Ralf Gutzmer(Medizinische Hochschule Hannover)Jochen Utikal(German Cancer Research Center)Daniela Göppner(University Hospital Magdeburg)Jessica C. Hassel(Heidelberg University)Friedegund MeierJulia K. Tietze(Ludwig-Maximilians-Universität München)Ioannis Thomas(University Children's Hospital Tübingen)Carsten Weishaupt(University Hospital Münster)Martin Leverkus(RWTH Aachen University)R.U. Wahl(RWTH Aachen University)Ursula M. DietrichClaus Garbe(University Children's Hospital Tübingen)Michael Constantin Kirchberger(Friedrich-Alexander-Universität Erlangen-Nürnberg)Thomas Eigentler(University Children's Hospital Tübingen)Carola Berking(Ludwig-Maximilians-Universität München)Anja Gesierich(Universitätsklinikum Würzburg)Angela M. Krackhardt(Technical University of Munich)Dirk Schadendorf(University of Duisburg-Essen)Gerold Schuler(Friedrich-Alexander-Universität Erlangen-Nürnberg)Reinhard Dummer(University Hospital of Zurich)Lucie Heinzerling✉(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Cancer Immunotherapy and BiomarkersCAR-T cell therapy researchMelanoma and MAPK PathwaysNivolumabMedicinePembrolizumabIpilimumabSide effect (computer science)Gastrointestinal tractEndocrine systemAdverse effectPancreasCancer
MeSH terms
IpilimumabNivolumabAdultAgedAntibodies, MonoclonalAntineoplastic AgentsDrug EruptionsEndocrine System DiseasesFemaleGastrointestinal DiseasesHumansKidney DiseasesMelanomaMiddle AgedRetrospective Studies
Citations
638
FWCI
45.70
field-weighted impact
References
51
Percentile
100%
vs. same field & year
Citations per year
Cited by
Guidelines of care for the management of primary cutaneous melanoma
Journal of the American Academy of Dermatology · 2018 · 692 citations
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2017 · 2,321 citations
References
Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
Immunity · 1999 · 2,706 citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
New England Journal of Medicine · 2010 · 15,037 citations
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Journal of Clinical Oncology · 2014 · 2,198 citations
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
The Lancet Oncology · 2015 · 2,648 citations
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 8,491 citations
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
New England Journal of Medicine · 2012 · 12,531 citations
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
New England Journal of Medicine · 2015 · 8,055 citations
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Annals of Oncology · 2015 · 1,449 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.
